Dermatology - European Medical Journal

Continue

Dermatology

Filter
11 Mins
10 Feb 2021

Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis

Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…
8 Mins
15 Dec 2020

The Other Side of the Moon: A Clinical Dialogue on the IL-23 Pathway

Prof Reich began by highlighting how insights into the pathophysiology of psoriasis have led to the development and expansion of cytokine-targeted…
Derm 8.1 feature image
6 Mins
15 Dec 2020

Latest Highlights on Biologic Treatments for Psoriasis and Psoriatic Arthritis from EADV 2020

The VOYAGE 1 trial1 was a placebo- and active-controlled Phase III study to evaluate long-term efficacy and safety of the IL-23p19 inhibitor guselkumab…
Derm 8.1 feature image
8 Mins
15 Dec 2020

Bimekizumab Efficacy and Safety in Patients with Moderate-to-Severe Plaque Psoriasis

Psoriasis is a Th17-driven disease, with both IL-17A and IL-17F playing a pivotal role in its pathogenesis.2,3 BKZ is a monoclonal IgG1 antibody…
9 Mins
15 Dec 2020

Editor’s Pick: Managing Chronic Urticaria: Quo Vadis?

Chronic urticaria (CU) is one of the most commonly diagnosed skin conditions. CU is characterised by the presence of recurrent wheals and/or angioedema…
8 Mins
15 Dec 2020

Impaired Mitochondrial and Metabolic Function of Fibroblasts Derived from Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosa (RDEB) and junctional EB (JEB) are inherited disorders characterised by fragility and blistering of epithelial…
11 Mins
15 Dec 2020

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors

With the recent advancements of biologic therapies that block IL-23, there is increasing need for analysis of which biologics are most efficacious…
4 Mins
15 Dec 2020

Case Report: Suspected Case of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Overlap Due to Ursodeoxycholic Acid

Stevens–Johnson syndrome and toxic epidermal necrolysis are well-known severe cutaneous adverse reactions, with >100 medications previously implicated…
We’ve noticed you’re accessing
from North/South America.